Omega-3 Index, fish consumption, use of fish oil supplements and first clinical diagnosis of central nervous system demyelination

Ausimmune Investigator Group, Alison Daly, Christopher Martin, Jill Sherriff, Trevor A. Mori, Gavin Pereira, Robyn M. Lucas, Anne Louise Ponsonby, Bruce Taylor, Ingrid van der Mei, Lucinda J. Black

Research output: Contribution to journalArticlepeer-review

Abstract

Higher intakes of omega-3 polyunsaturated fatty acids (n3PUFAs) have been associated with lower MS risk. We aimed to test associations between the Omega-3 Index, blood levels of n3PUFAs, fish oil supplement use, and fish consumption with a first clinical diagnosis of CNS demyelination (FCD). Cases (n = 250) had a higher Omega-3 Index compared with a matched group of controls (n = 471) (average treatment effect (ATE)=0.31, p = 0.047, based on augmented inverse probability weighting). A higher percentage of cases than controls used fish oil supplements (cases=17% vs. controls=10%). We found that Omega-3 Index increased as time between FCD and study interview increased (e.g., at or below median (112 days), based on ATE, mean=5.30, 95% CI 5.08, 5.53; above median, mean=5.90, 95% CI 5.51, 6.30). Fish oil supplement use increased in a similar manner (at or below median (112 days), based on ATE, proportion=0.12, 95% CI 0.06, 0.18; above the median, proportion=0.21, 95% CI 0.14, 0.28). Our results suggest a behaviour change post FCD with increased use of fish oil supplements.

Original languageEnglish
Article number103210
JournalMultiple Sclerosis and Related Disorders
Volume55
DOIs
Publication statusPublished - Oct 2021

Fingerprint

Dive into the research topics of 'Omega-3 Index, fish consumption, use of fish oil supplements and first clinical diagnosis of central nervous system demyelination'. Together they form a unique fingerprint.

Cite this